NCT05938673Completed
Effects of rTSMS Associated With Treadmill Training in Patients With Parkinson's Disease
Effects of Repetitive Trans Spinal Magnetic Stimulation Associated With Treadmill Gait Training on Gait Disorders in Patients With Parkinson's Disease
Source: ClinicalTrials.gov · Last updated 2 Mar 2026
Brief summary (registry, in English)
Gait changes appear and become the main cause of disability, loss of independence, falls, fractures and reduced quality of life for patients with Parkinson Disease. Optimal gait management is complex and challenging. Some characteristics, such as gait variability, postural instability, and postural changes, continue to worsen over time despite optimal dopaminergic treatment, suggesting that additional interventions are needed. Given the physiology of gait and postural control in humans, spinal cord stimulation is a potential target for neuromodulatory approaches to gait and postural disorders. Repetitive transspinal magnetic stimulation ( rTSMS) has attracted a lot of attention, due to the possibility of modulating motor and sensory networks in a non-invasive way, activating directly the dorsal ascending pathways and projecting to the thalamic nuclei, cerebral cortex, and brainstem nuclei, thus stimulating descending motor tracts and interrupting aberrant oscillatory activity in corticobasal nuclei circuits. The combination of non-invasive neuromodulation with other therapies can enhance the effectiveness of rehabilitation, increasing plasticity and clinical efficacy, offering a greater and more sustained effect than either therapy alone.It's recommended that patients with PD perform a specific exercise for walking, such as treadmill training (tt), that imposes an external rhythm and concentration of attention on gait, acting as an external cue or marker, promoting a more stable gait, reducing gait variability and decreasing risk of falls. It is proposed, in this study, to develop a new treatment model through the integration of two promising and complementary approaches to improve gait disorders in PD: rTSMS and tt. Thus, the investigators idealized the realization of the first randomized, double-blind, placebo-controlled, parallel, phase III clinical trial that will evaluate the efficacy of tt associated with rTSMS in patients with PD.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 76 (actual)
- First submitted
- 2 Jun 2023
- Start date
- 1 Jun 2023
- Primary completion date
- 1 Jun 2023
- Lead sponsor
- University of Sao Paulo General Hospital
- Diseases
- Parkinson disease
- NCT number
- NCT05938673
What you commit to
- Study type: Interventional
- Participants enrolled: 76
- From 1 Jun 2023 to the primary completion date, 1 Jun 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Individuals with labyrinthine problems, using medication that may interfere with balance and performance in tests and treadmill training will be excluded.
- Individuals who have undergone deep brain stimulation surgery or epidural spinal cord stimulation will be excluded.
- Concomitant treatment with other experimental drugs;
Other illness
- Patients with unstabilized psychiatric comorbidities;
- Individuals who have other neurological disorders, musculoskeletal, orthopedic, cardiovascular and respiratory disorders that may affect the ability to walk on the treadmill will be excluded.
- Patients with uncontrolled infection or other uncontrolled pre-existing medical conditions (eg uncontrolled diabetes, high blood pressure, symptomatic lung or heart disease);
- Patients with metal implants and a cardiac pacemaker.
- Patient with a history of neurosurgery.
Other
- Pregnant or breastfeeding women.
- Presence of chronic low back and lower limb pain.
- Patients who cannot walk without assistance (cane, crutch, walker) or help from another person.
Who the study is looking for
- Men and women over the age of 18;
- Participants with PD at Hoehn Yahr stages between 2 and 4 (moderate disease) while on-medication (i.e., at the time when their usual dopaminergic medication is clinically effective), whose primary symptom includes gait disturbance (score equal to or greater than 1 in subitem 2.12 of the MSD-UPDRS scale). Patients will be evaluated for the presence of freezing gait (freezing) through the Freezing of Gait Score (FOG-SCORE).
- While on on-medication, be able to walk independently for 30 meters or with a unilateral assistive device.
- Mini Mental State Examination (MMSE) score greater than or equal to 23.
- Sign the informed consent form.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital das Clinicas da Faculdade de Medicina da USP Coordinator of this site? Confirm its status | São Paulo | Brazil | Unknown status |
Related publications
- Trans-spinal theta burst magnetic stimulation combined with treadmill training for gait disorders in Parkinson's disease: A randomized clinical trial.Parkinsonism Relat Disord · 2026 · PMID 42664922
This page is information, not medical advice. Discuss any trial with your doctor.